Research teams link response to Iressa to mutations in EGF receptor.
SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.
Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.
NCI blocked groups from phase III Iressa studies.
Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.
Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.
Funding opportunities listed.
April issue of Business & Regulatory Report included (8 additional pages).
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
